Key statistics
On Friday, Dyadic International Inc (DYAI:NAQ) closed at 0.76, 6.89% above its 52-week low of 0.711, set on Aug 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.775 |
|---|---|
| High | 0.80 |
| Low | 0.76 |
| Bid | 0.76 |
| Offer | 0.81 |
| Previous close | 0.7644 |
| Average volume | 100.16k |
|---|---|
| Shares outstanding | 36.19m |
| Free float | 26.87m |
| P/E (TTM) | -- |
| Market cap | 27.66m USD |
| EPS (TTM) | -0.2371 USD |
Data delayed at least 15 minutes, as of Mar 13 2026 20:00 BST.
More ▼
- Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
- Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
- Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
- Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
- Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
- Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins
- Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
- Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
- Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
- Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
More ▼
